Xylazine can be detected using inexpensive test strips at home or in the field, or through advanced laboratory testing on blood and urine samples. In 2023, 30% of fentanyl powder seized by the DEA contained xylazine, making testing increasingly relevant for harm reduction, clinical care, and forensic investigation. The right method depends on whether you’re checking a substance before use, confirming exposure in a patient, or identifying xylazine in a forensic case.
Using Xylazine Test Strips
Xylazine test strips (XTS) are the most accessible option. They work like a pregnancy test: dip the strip into a prepared solution, wait a few minutes, and read the result. These lateral flow immunoassay strips reliably detect xylazine at concentrations of 2.5 micrograms per milliliter or higher. In validation studies, they achieved 97.4% sensitivity, perfect specificity, and 98.6% overall accuracy. That means they catch nearly all positive samples and produce virtually no false positives.
The one known exception is lidocaine. Research from Johns Hopkins Bloomberg School of Public Health found that lidocaine is the only identified substance that can trigger a false positive on xylazine test strips. If your sample contains lidocaine (a common cutting agent in street drugs), a positive result may not necessarily mean xylazine is present.
How to Use Them
New York City’s Department of Health provides clear instructions that reflect the standard method. Place at least 10 milligrams of the substance in a clean, dry container. Ten milligrams is roughly enough to cover Abraham Lincoln’s hair on a penny. Add one teaspoon (5 milliliters) of water for every 10 milligrams and stir. If you can’t measure out 10 milligrams, put a few grains in a container, or empty your bag, add water to the residue left inside, and test that. Dip the strip into the solution according to the package directions and read the result within the specified time window.
The dilution ratio matters. Too much drug relative to water can overwhelm the test and actually cause a false negative, a phenomenon called the “hook effect.” Following the one-teaspoon-per-10-milligrams ratio avoids this problem.
Legal Status of Test Strips
Test strips for drug checking have historically been classified as drug paraphernalia in many states, but laws are changing. Ohio, for example, exempted xylazine test strips from its paraphernalia laws effective October 2025, allowing legal possession and distribution. Many other states have passed similar harm reduction exemptions in recent years. The legal landscape varies significantly by state, so check your local laws before purchasing or distributing strips.
Clinical and Laboratory Testing
Standard hospital drug screens do not test for xylazine. It is not an opioid, a benzodiazepine, or an amphetamine, so it won’t show up on the typical panels run in emergency departments. If a clinician suspects xylazine exposure, they need to specifically order testing for it.
The gold standard for confirming xylazine in biological samples is a technique called liquid chromatography paired with mass spectrometry (LC-MS/MS). This method can detect xylazine in blood and urine at concentrations below 1 nanogram per milliliter, which is roughly a thousand times more sensitive than test strips. Sample preparation is straightforward, often requiring just a basic dilution step, and the analysis itself takes only a few minutes. A related technique using a different type of mass spectrometry instrument achieves similar sensitivity while also screening for a broader range of substances in the same run.
Earlier methods relied on gas chromatography with mass spectrometry (GC-MS), and some labs still use this approach. Both methods are considered definitive, but LC-MS/MS has become the preferred tool because of its speed and sensitivity. The catch is that these instruments are expensive and require specialized technicians, so testing is limited to regional reference laboratories. Most community hospitals send samples out, which means results can take days.
Detection Windows in Urine and Blood
Xylazine leaves the body relatively quickly compared to many other drugs. Its urinary half-life ranges from about 1 to 25 hours, a wide spread that reflects differences in metabolism, dose, and frequency of use. Based on those half-life estimates, the predicted detection window in urine is roughly 14 hours to 5 days after exposure. For someone with a single, smaller exposure, the window may close within a day. Chronic or heavy exposure extends it toward the five-day end.
Blood concentrations tend to be lower than urine concentrations, making urine the more practical specimen for clinical testing. If you or a clinician want to confirm recent xylazine exposure, urine is the better sample to submit, and timing matters. Testing within the first 48 hours gives the best chance of a positive result.
When Clinicians Should Suspect Xylazine
Xylazine doesn’t always announce itself. But certain clinical signs raise suspicion. The most distinctive marker is severe, necrotic skin ulcerations at or near injection sites. These wounds look different from the cellulitis or abscesses typically associated with injection drug use. They involve tissue death and can worsen rapidly, sometimes appearing at sites distant from where the injection actually occurred.
Acute xylazine toxicity can also present as an unusual combination of very low heart rate and low blood pressure occurring together, along with respiratory depression, low body temperature, constricted pupils, and elevated blood sugar. Perhaps the most important clinical clue comes during overdose reversal: if someone experiencing an apparent opioid overdose does not respond as expected to naloxone, xylazine exposure should be considered. Naloxone reverses opioid effects but does nothing to counter xylazine, so the person may remain sedated or continue to deteriorate even after appropriate naloxone dosing.
Forensic and Post-Mortem Detection
Identifying xylazine in deceased individuals presents its own challenges. Blood is the standard specimen in forensic toxicology, but xylazine concentrations in blood tend to be the lowest of any tissue tested. Urine concentrations run much higher and are more reliable. Heart blood, which is commonly collected at autopsy, is particularly problematic because of a phenomenon called post-mortem redistribution, where drugs migrate between tissues after death and skew concentration measurements.
Forensic pathologists working xylazine cases are advised to collect a wider range of specimens than usual. Beyond the standard heart blood, liver, and stomach contents, tissues like brain and muscle are less affected by post-mortem redistribution and may give more accurate readings. In cases where the suspected route of exposure was injection, tissue from the injection site itself provides the most direct evidence. There is no universally agreed-upon “best” specimen for forensic xylazine detection, so collecting multiple sample types gives the most complete picture.